Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections

T. W. Cheung, D. T. Jayaweera, D. Pearce, P. Benson, R. Nahass, C. Olson, G. M. Wool

Research output: Contribution to journalArticle

7 Scopus citations


We undertook a study to compare the safety of intravenous (i.v.) versus oral hydration to prevent nephrotoxicity associated with the use of foscarnet for induction therapy of cytomegalovirus (CMV) infection in HIV-infected persons. Patients, given foscarnet at a dose of 90mg/kg every 12h, were randomized to receive either i.v. or oral hydration. Thirty-seven patients were given i.v. hydration and 44 were given oral hydration. Median duration of therapy for both groups was 17 days. There was no difference between the 2 groups in either serious adverse events or rise of creatinine to ≥2.0mg/dl. However, serum creatinine, while generally remained within normal limits, increased more in patients who received oral hydration after 10 days of therapy (significant only by slope analysis, P < 0.05). Although i.v. hydration provided better protection against nephrotoxicity, oral hydration was relatively safe and convenient provided that creatinine clearance (CrCl) is monitored closely.

Original languageEnglish (US)
Pages (from-to)640-647
Number of pages8
JournalInternational Journal of STD and AIDS
Issue number10
StatePublished - Nov 9 2000



  • Cytomegalovirus infection
  • Foscarnet
  • Intravenous hydration HIV
  • Nephrotoxicity
  • Oral hydration

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Immunology

Cite this